Pharmacology and macrophage modulation of HPGDS inhibitor PK007 demonstrate reduced disease severity in DMD-affected muscles of the mdx mouse model
This study lays a strong foundation for progressing the use of HPDGS inhibitors such as PK007, which specifically inhibit PGD2 and reduce inflammation, as a viable therapeutic approach for DMD. This approach protects dystrophic muscles from necrosis and reduces the severity of this debilitating disease, improving outcomes and quality of life.
Authors
- Miranda D. Grounds (ORCID: https://orcid.org/0000-0002-4530-9402)
- Sai Yarlagadda (ORCID: https://orcid.org/0000-0001-7352-2246)
- Peter G. Noakes (ORCID: https://orcid.org/0000-0001-9821-8478)
- Mark L. Smythe (ORCID: https://orcid.org/0000-0001-7840-1021)
- Chynna-Loren Sheremeta
- Sang Won Cheung
- Alison Cuffe
Institutions
- The University of Queensland (AU)
- The University of Western Australia (AU)
Publication Details
- Journal
- Skeletal Muscle
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1186/s13395-025-00379-1
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health and Medical Research Council